| ACE2 | Angiotensin-converting enzyme 2 |
| AIDS | Acquired immunodeficiency syndrome |
| ARDS | Acute respiratory distress syndrome |
| CBC | Cannabichromene |
| CBCA | Cannabichromenic acid |
| CBD | Cannabidiol |
| CBDA | Cannabidiolic acid |
| CBDV | Cannabidivarin |
| CBDVM | Cannabidivarin methyl ester |
| CBE | Cannabielsoin |
| CBG | Cannabigerol |
| CBL | Cannabicyclol |
| CBN | Cannabinol |
| CBT | Cannabitriol |
| CBV | Cannabivarin |
| CDC | Centers for disease control and prevention |
| CNS | Central nervous system |
| DNA | Deoxyribonucleic acid |
| EC | Endocannabinoid |
| EO | Essential oil |
| FDA | Food and drug administration |
| GNB | Gram-negative bacteria |
| GPB | Gram-positive bacteria |
| HMVEC | Human microvascular endothelial cells |
| HOMO | Highest occupied molecular orbital |
| IL | Interleukin |
| KSHV | Kaposi sarcoma associated herpesvirus |
| LPS | Lipopolysaccharide |
| LUMO | Lowest unoccupied molecular orbital |
| MBEC | Minimum biofilm eradication concentration |
| MD | Molecular dynamic |
| MIC | Minimum inhibitory concentration |
| MRSA | Methicillin-resistant Staphylococcus aureus |
| MSSA | Methicillin-susceptible Staphylococcus aureus |
| MV | Membrane vesicle |
| PBP | Penicillin-binding proteins |
| QIDP | Qualified infectious disease product |
| QSAR | Quantitative structure-activity relationship |
| RNA | Ribonucleic acid |
| R&D | Research and Development |
| SARS-CoV | Severe acute respiratory syndrome coronavirus |
| THC | Tetrahydrocannabinol |
| THCA | Tetrahydrocannabinolic acid |
| TMPRSS2 | Transmembrane protease, serine 2 |
| TNF-α | Tumor necrosis factor |
| VISA | Vancomycin-intermediate Staphylococcus aureus |
| VRSA | Vancomycin-resistant Staphylococcus aureus |
| WHO | World health organization |